Ascendis Pharma A/S (ASND)
$223.21-1.67%Close
SELLRECOVERY · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $13.9B
- Beta
- 0.37
- P/E (TTM)
- 16.46
- Short % float
- 5.66%
- Days to cover
- 3.7
- SI change
- -12.1%
- 1W
- -1.26%
- 1M
- -15.74%
- vs SPY 1W
- -1.12%
- vs SPY 1M
- -18.25%
Industry peers
FMP comparable companies · ranked by market cap
- UTHRBUYUnited Therapeutics Corporation$23.3BRECOVERYQ 20$549.16-1.22%
- INSMSELLInsmed Incorporated$21.8BCRISISQ 13$100.60-1.80%
- NBIXSELLNeurocrine Biosciences, Inc.$14.3BRECOVERYQ 16$142.44-4.41%
- CORTBUYCorcept Therapeutics Incorporated$13.1BBULLQ 21$121.19-2.80%
- BMRNSELLBioMarin Pharmaceutical Inc.$10.6BBEARQ 12$54.80-1.82%
- MBXSELLMBX Biosciences, Inc. Common Stock$2.5BCRISISQ 36$53.24-5.81%
- XERSBUYXeris Biopharma Holdings, Inc.$1.8BBULLQ -1$10.48-2.49%
- SEPNSELLSepterna Inc$1.7BRECOVERYQ 26$38.37-3.04%
- STOKSELLStoke Therapeutics, Inc.$1.6BCRISISQ 10$24.74-6.83%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.5BRECOVERYQ -6$15.48-2.48%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ASND?
- LOPJLB’s latest quantitative signal on Ascendis Pharma A/S (ASND) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is ASND in?
- Ascendis Pharma A/S (ASND) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Ascendis Pharma A/S (ASND) do?
- Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. T…